VICL (Vical Labs) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VICL (Vical Labs)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: bob zagorin	2/15/2006 2:56:58 PM
	of 1972

GS on VICL Vical Inc. EPS (FY Dec) 2006E ($0.92), 2007E ($1.02) Underperform/Neutral (VICL) $4.11 Vical reported Q4/05 loss of $0.20 ex-ESO, versus our and consensus estimates $0.17 and $0.21 respectively, on lower contract revenue. During Q4/05, VICL made progress on DNA vaccines, including (1) initiating P2 trials on CMV and HIV (2) received $1MM milestone fee from Merck, which started a P1 cancer trial and (3) completed 1st milestone in NIH avian flu program. VICL also plans to begin enrollment of the 5mg dose cohort for IL2 electroporation therapy of melanoma. VICL has a broad technology platform in DNA gene delivery, solid partners, and years cash position. We maintain our Underperform rating while awaiting progress on proprietary projects. Our coverage view remains Neutral. Risks to our rating include acceleration of pipeline, avian flu pandemic, and acquisition potential.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next